FY 2019 Update

DRAFT R&D SECTION

Christian Heidbreder, CSO 1/17/20
TREATMENT OF OPIOID USE DISORDER (OUD)

SUBLOCADE® (BUPRENORPHINE EXTENDED-RELEASE) INJECTION:

- In the US:
  ▪ All Post Marketing Requirement (PMR) and Commitment (PMC) studies are on track.
  ▪ Lifecycle Evidence Generation & Optimization (LEGO) Studies: These studies are dedicated to (1) understand the use of diverted buprenorphine (see our publication list); (2) assess how to induce SUBLOCADE® treatment in the emergency department environment, and (3) investigate how high plasma concentrations of buprenorphine, consistent with those delivered by the two approved dosing regimens of SUBLOCADE®, could potentially block the effects of respiratory depression produced by fentanyl. All studies are on track.
  ▪ We pursued the analysis of patient-centered outcomes in our Phase III RB-US-13-0001 and RB-US-13-0003 trials. Several manuscripts were submitted and published in peer-reviewed journals (see publication list).
  ▪ The RECOVER™ (REmission from Chronic Opioid Use: Studying EnVironmental and socioEconomic factors on Recovery) study achieved 534 subjects completing 12-month longitudinal analysis. A manuscript was submitted and is currently under peer-review. The final 24-month report was finalised on December 17, 2019 and a peer-reviewed publication is in preparation. The scope and duration of these assessments may lead to important new insights into models of recovery and allow researchers, clinicians, and patients to more accurately characterize the process of recovery, identify factors that promote or hinder success, and potentially develop new and personalized treatment strategies. In order to strengthen this approach, Indivior announced a new partnership with the Virginia Polytechnic Institute and State University (Virginia Tech).

- Ex-US Regulatory Activities:
  ▪ Canada: SUBLOCADE® approval on November 21, 2018.
  ▪ Australia: SUBLOCADE® approval on July 17, 2019.
  ▪ Ex-US regulatory filings: Filings were made in Israel (July 2018), New Zealand (September 2018) and Europe (November 2018). Reviews by local Regulatory Authorities are ongoing.

SUBOXONE® (BUPRENORPHINE / NALOXONE) FILM:

- Canada: Supplemental New Drug Submission (SNDS) filed June 27, 2019; Screening acceptance letter received September 23, 2019. Regulatory Authority review is ongoing.
- Israel: Submission on September 3, 2018. Regulatory Authority review is ongoing.
- New Zealand: Regulatory dossier submitted October 30, 2019. Regulatory Authority review is ongoing.
- Middle East: Regulatory dossier submissions in Kingdom of Saudi Arabia, United Arab Emirates, Qatar and Kuwait are planned for 2020 pending registration agreement with local distributors.
**SUBOXONE® (buprenorphine / naloxone) Tablet:**
- On September 11, 2018, the Chinese National Medical Products Administration (NMPA) approved SUBOXONE® Sublingual Tablets for the treatment of opioid use disorder.
- On February 4, 2019, Indivior announced a definitive agreement to divest the rights related to SUBOXONE® Sublingual Tablets (Sai Bo Song™) in China to Zhejiang Pukang Biotechnology Co., Ltd. The agreement is subject to various closing conditions (ongoing).

**TREATMENT OF SCHIZOPHRENIA**

**PERSERIS™ (formerly RBP-7000), Monthly Long-Acting Risperidone Injection:**
- PMC studies on track.
- Canada: HLS Therapeutics and Indivior held an Integration kick-off meeting on June 14, 2019. The NDS was submitted to Health Canada on November 7, 2019. Regulatory review is ongoing.

**EARLY STAGE ASSET DEVELOPMENT (ESAD)**

- **GABA positive allosteric modulator:**
  - New lead identification and optimization program is ongoing in partnership with ADDEX Therapeutics.
- **C4X3256 (Selective Orexin 1 (OX1) receptor antagonist):**
  - On September 26, 2019 the National Institutes of Health (NIH) granted Indivior’s application entitled “Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder” pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose. A link to Indivior’s Press Release can be found here.
  - A pre-investigational new drug application (PIND) application was submitted to the FDA on September 20, 2019. FDA feedback was received on January 2, 2020. First-In-Human protocol has now been finalized and the IND was filed on January 17, 2020.
  - Our development plans were presented at the first HEAL Investigator Meeting in Bethesda on January 16-17, 2020.
- **APV202701A (Selective dopamine [DA] D3 receptor antagonist):**
  - Initiation of IND-related activities and dossier preparation in partnership with Aptuit.
PEER-REVIEWED PUBLICATIONS (2019)


CONFERENCE ABSTRACTS (2019)


